Kaiting Yang

Kaiting Yang focuses her practice on initial public offerings (IPOs) and other equity capital markets transactions on the Hong Kong Stock Exchange (HKEX), pre-IPO investments, public takeovers, and listing rules and securities regulations compliance. Kaiting has been actively involved in the pre-IPO financing and IPO process for biotech companies seeking to list on the HKEX, as well as in regulatory compliance for biotech companies listed on the HKEX, in particular, Ascletis Pharma Inc. (HKEX: 1672), the first pre-revenue biotech company listed on the HKEX under the new listing regime for companies in emerging and innovative sectors.

Prior to joining Cooley, Kaiting has worked at the Hong Kong office of another leading US law firm.

Kaiting is a native Mandarin speaker and is fluent in English and Cantonese.

Representative Matters:

Capital Markets

• Joint sponsors and underwriters Morgan Stanley, Jefferies, CITIC Securities, CICC and CMB International Securities on HK$1.64 billion IPO and listing of Duality Biotherapeutics, a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases
• Joint sponsors and underwriters CICC and CMB International Securities on HK$$1.005 billion IPO and listing of Zenergy, a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products
• VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, on its HK$783 million IPO and listing on HKEX
• CICC and Huatai International as placing agent for the placing of existing shares in Black Sesame International Holding Limited in the amount of HK$1.24 billion
• Joint sponsors and underwriters CICC and SPDB International on HK$583 million Hong Kong IPO of BrainAurora Medical Technology, a seasoned player in China's cognitive impairment digital therapeutics (DTx) market
• Joint sponsors CICC, Citigroup and China Renaissance on US$285 million H shares IPO and listing of Huitongda Network Co., Ltd., a leading e-commerce company backed by Alibaba, on HKEX
• ImmuneOnco, a clinical-stage biotech company, on its HK$319 million Hong Kong IPO, and HK$234 million follow-on offering
• Joint sponsors and underwriters Citi and Huatai International on Cryofocus Medtech's HK$210 million IPO and listing on HKEX
• Jacobio Pharmaceuticals’ placement of existing shares and top-up subscription of new share under general mandate totaling HK$160.4 million
• STAR CM, a variety program intellectual property creator and operator, on its HK$390 million IPO and listing on HKEX
• Asymchem, a leading contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its US$818 million IPO and listing on the Hong Kong Stock Exchange. This is the largest healthcare HK IPO in 2021
• Keymed Biosciences, a China-based biotechnology company focused on in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas, in its US$400 million Hong Kong IPO and global offering
• CStone Pharmaceuticals (HKEX: 2616) in its strategic collaboration with Pfizer Inc. (NYSE: PFE) which involves a 200 million equity investment by Pfizer in CStone, a collaboration for the development and commercialization of CStone’s core product (CS1001, PD-L1 antibody) in mainland China, and a framework to bring additional oncology assets to the Greater China market
• Fangdd Network Technology, one of China’s largest online real estate platforms, in its initial public offering of American depositary shares and listing on Nasdaq
• Alphamab Oncology, a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in biospecifics and protein engineering, in its Series B Financing and US$234 million Hong Kong IPO and global offering
• Chinese property developer on its proposed IPO on the HKEX and global offering
• CLSA Limited as the Placing Agent in the placing of existing shares and top-up subscription of new shares in China New Higher Education Group Limited in the amount of HK$393 million
• ABCI Capital Limited and China Securities (International) Corporate Finance Company Limited as the underwriters and Joint Sponsors and other underwriters in the US$503 million Hong Kong IPO on the HKEX of Bank of Jiujiang Co., Ltd.
• China Everbright Greentech Limited, a subsidiary of China Everbright Group involving in business segments including waste to energy, water treatment and solar energy, on its spin-off listing and US$424 million Hong Kong IPO on the HKEX
• China International Capital Corporation, a leading China-based investment bank, in its US$708 million Hong Kong IPO and global offering
• BofA Merrill Lynch and Morgan Stanley as underwriters in the US$355 million Regulation S and 144A International offering of ordinary shares by Star Petroleum Refinery Corporation Limited in connection with its Thai IPO

Listed issuer’s Compliance

• ImmuneOnco Biopharmaceuticals (HKEX: 1541) on its Hong Kong compliance matters
• Ascletis Pharma Inc. (HKEX: 1672) on its Hong Kong compliance matters
• Hilong Holding Limited (HKEX: 1623) on its Hong Kong compliance matters
• CNOOC Limited (HKEX: 0883) on its Hong Kong compliance matters
• Shanghai Yongda Automobiles Services Holdings Limited (HKEX: 3669) on its Hong Kong compliance matters and its spin-off for its proposed A share offering
• Mongolia Mining Corporation (HKEX: 0975) on its Hong Kong compliance matters
• Longfor Properties Co. Ltd. (HKEX: 0960) on its compliance obligations as listed issuer in its proposed debt offering

Others

• Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, on a US$105 million equity investment by AstraZeneca
• Brii Biosciences (HKSE: 2137) in its agreements with VBI Vaccines (NASDAQ: VBIV) to acquire the IP for BRII-179 (VBI-2601), the manufacturing capabilities and assets of manufacturing facility in Rehovot, Israel, and an exclusive license to develop and commercialize VBI-1901 in Asia Pacific excluding Japan.
• Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, in its exclusive license agreement with argenx SE (Euronext & NASDAQ: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, to develop and commercialize argenx’s FcRn blocking antibody product, efgartigimod, in Greater China (mainland China, Hong Kong, Macau and Taiwan).
• CStone Pharmaceuticals (HKEX: 2616) on its strategic collaboration with Pfizer Inc. (NYSE: PFE) which involves US$200 million equity investment by Pfizer in CStone, a collaboration for the development and commercialization of CStone’s core product (CS1001, PD-L1 antibody) in mainland China, and a framework to bring additional oncology assets to the Greater China market